問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Digestive System Department

Division of General Internal Medicine

Division of Radiation Therapy

Division of Hematology & Oncology

更新時間：2023-09-19

王景弘Wang, Jing-Houng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • wajing@cgmh.org.tw

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王景弘

List

86Cases

2007-11-20 - 2009-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2022-07-01 - 2027-02-26

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting4Sites

Recruiting4Sites

2017-09-01 - 2019-01-03

Others

Completed
A Phase 2a, randomized, double-blind, placebo-controlled, dose-ranging, parallel group study to evaluate safety, tolerability, and pharmacodynamics of PF-05221304 administered daily for 16-weeks to adult subjects with nonalcoholic fatty liver disease

  • Condition/Disease

    nonalcoholic fatty liver disease

  • Test Drug

    PF-05221304

Participate Sites
7Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2017-11-01 - 2027-12-31

Phase III

Active
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    Durvalumab/ Tremelimumab

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

陳三奇
Taipei Veterans General Hospital

Division of Hematology & Oncology

2023-01-30 - 2028-11-27

Phase II

Active
A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    MEDI5752 AVASTIN LENVIMA AZD2936

Participate Sites
8Sites

Recruiting8Sites

2018-11-30 - 2025-12-31

Phase III

Active
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)

  • Condition/Disease

    Locoregional Hepatocellular Carcinoma

  • Test Drug

    DURVALUMAB (IMFINZI, MEDI4736)

Participate Sites
10Sites

Recruiting9Sites

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

2023-09-01 - 2027-04-30

Phase II

Active
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Budigalimab (ABBV-181)；Livmoniplimab (ABBV-151)

Participate Sites
9Sites

Not yet recruiting3Sites

Recruiting6Sites

2023-10-31 - 2027-08-31

Phase III

Active
A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate the Safety and Efficacy of Systemic Therapy With Regorafenib and Pembrolizumab Versus Locoregional Therapy With Transarterial Chemoembolization or Transarterial Radioembolization, for the First-line Treatment of Intermediate-stage Hepatocellular Carcinoma With Beyond Up-to-7 Criteria

  • Condition/Disease

    Carcinoma, Hepatocellular

  • Test Drug

    Regorafenib Keytruda injection/Keytruda

Participate Sites
8Sites

Not yet recruiting7Sites

Recruiting1Sites

2021-12-30 - 2025-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-07-06 - 2025-05-31

Others

Active
An Open-label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors

  • Condition/Disease

    Endometrial Neoplasms

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Terminated6Sites

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB